[go: up one dir, main page]

MA29542B1 - Traitement des maladies hepatiques dans la pathogenese desquelles le fer joue un role - Google Patents

Traitement des maladies hepatiques dans la pathogenese desquelles le fer joue un role

Info

Publication number
MA29542B1
MA29542B1 MA30467A MA30467A MA29542B1 MA 29542 B1 MA29542 B1 MA 29542B1 MA 30467 A MA30467 A MA 30467A MA 30467 A MA30467 A MA 30467A MA 29542 B1 MA29542 B1 MA 29542B1
Authority
MA
Morocco
Prior art keywords
treatment
pathogenesis
role
hepatic diseases
iron plays
Prior art date
Application number
MA30467A
Other languages
English (en)
Inventor
Daniele Alberti
Peter Marks
Hanspeter Nick
Lisa Grace Rojkjaer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA29542B1 publication Critical patent/MA29542B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Addiction (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'INVENTION CONCERNE L'UTILISATION D'ACIDE 4-[3,5-BIS-(2-HYDROXYPHÉNYL)-[1,2,4]-TRIAZOL-1-YL]BENZOÏQUE (APPELÉ ICI 'COMPOSÉ I') DANS LA FABRICATION DE COMPOSITIONS PHARMACEUTIQUES UTILES DANS LE TRAITEMENT DE MALADIES HÉPATIQUES HUMAINES DANS LA PATHOGENÈSE DESQUELLES LE FER JOUE UN RÔLE, NOTAMMENT DES MALADIES VIRALES, TELLES QUE L'HÉPATITE C CHRONIQUE, FACULTATIVEMENT ASSOCIÉES À DES AGENTS ANTIVIRAUX, ET DANS LE TRAITEMENT DE MALADIES NON VIRALES, TELLES QUE LA STÉATOHÉPATITE NON ALCOOLIQUE ET LA STÉATOSE HÉPATIQUE NON ALCOOLIQUE.
MA30467A 2005-05-31 2007-12-10 Traitement des maladies hepatiques dans la pathogenese desquelles le fer joue un role MA29542B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68584805P 2005-05-31 2005-05-31
US69280805P 2005-06-22 2005-06-22
US74678606P 2006-05-09 2006-05-09

Publications (1)

Publication Number Publication Date
MA29542B1 true MA29542B1 (fr) 2008-06-02

Family

ID=37106984

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30467A MA29542B1 (fr) 2005-05-31 2007-12-10 Traitement des maladies hepatiques dans la pathogenese desquelles le fer joue un role

Country Status (16)

Country Link
US (3) US20080199428A1 (fr)
EP (1) EP1893198A2 (fr)
JP (2) JP2008542380A (fr)
KR (2) KR20080003933A (fr)
AU (1) AU2006252718B2 (fr)
BR (1) BRPI0610873A2 (fr)
CA (1) CA2608709A1 (fr)
CR (1) CR9454A (fr)
EA (1) EA014772B1 (fr)
IL (1) IL187000A0 (fr)
MA (1) MA29542B1 (fr)
MX (1) MX2007015085A (fr)
NO (1) NO20076595L (fr)
SM (1) SMAP200700061A (fr)
TN (1) TNSN07447A1 (fr)
WO (1) WO2006130532A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
MXPA02011691A (es) 2000-05-26 2004-05-17 Idenix Cayman Ltd Metodos y composiciones para el tratamiento de flavivirus y pestivirus.
CN101172993A (zh) 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷
JP2005533824A (ja) 2002-06-28 2005-11-10 イデニクス（ケイマン）リミテツド フラビウイルス科感染の治療のための２’−ｃ−メチル−３’−ｏ−ｌ−バリンエステルリボフラノシルシチジン
PL377342A1 (pl) 2002-11-15 2006-01-23 Idenix (Cayman) Limited Nukleozydy rozgałęzione w pozycji 2' oraz mutacja Flaviviridae
AU2003300901A1 (en) 2002-12-12 2004-06-30 Idenix (Cayman) Limited Process for the production of 2'-branched nucleosides
JP2009504706A (ja) * 2005-08-15 2009-02-05 エフ．ホフマン−ラ ロシュ アーゲー ＨＢＶ処置のためのＰＥＧ−ＩＦＮαおよびリバビリン
EP1927591A1 (fr) * 2006-11-29 2008-06-04 Novartis AG Formes polymorphes de deferasirox (ICL670)
KR20090085081A (ko) * 2006-11-29 2009-08-06 노파르티스 아게 데페라시록스 (ｉｃｌ６７０ａ)의 다형체 형태
CN103635196B (zh) * 2011-03-02 2019-05-07 J·深塔格 用于单独治疗肝脂肪变性或治疗伴有丙型肝炎病毒感染的肝脂肪变性的组合物、治疗方法和诊断方法
CA2811250C (fr) 2011-10-21 2015-08-11 Abbvie Inc. Methodes de traitement du vhc
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
SE1450019A1 (sv) 2011-10-21 2014-01-10 Abbvie Inc Förfaranden för att behandla HCV innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
EP2770990A4 (fr) * 2011-10-28 2015-03-11 Lumena Pharmaceuticals Inc Inhibiteurs du recyclage de l'acide biliaire pour traitement de l'hypercholémie et de la maladie cholestatique hépatique
RU2724339C2 (ru) * 2014-03-21 2020-06-23 Тобира Терапьютикс, Инк. Сенекривирок для лечения фиброза
EP3448392A4 (fr) 2016-04-28 2020-01-15 Emory University Compositions thérapeutiques à base de nucléotides et nucléosides contenant un alcyne et utilisations associées
GB202005054D0 (en) 2020-04-06 2020-05-20 Nemysis Ltd Carboxylate Ligand Modified Ferric Iron Hydroxide Compositions for Use in the Treatment or Prevention of Iron Deficiency Associated with Liver Diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW533205B (en) * 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
JP4125011B2 (ja) * 2002-01-22 2008-07-23 株式会社 伊藤園 過剰鉄起因肝障害予防・治療剤及び過剰鉄起因肝障害予防・治療飲食物

Also Published As

Publication number Publication date
CR9454A (es) 2008-04-16
IL187000A0 (en) 2008-02-09
AU2006252718B2 (en) 2010-04-15
SMAP200700061A (it) 2007-12-28
US20100098662A1 (en) 2010-04-22
EA200702384A1 (ru) 2008-06-30
WO2006130532A2 (fr) 2006-12-07
KR101174966B1 (ko) 2012-08-17
CA2608709A1 (fr) 2006-12-07
JP2013082726A (ja) 2013-05-09
AU2006252718A1 (en) 2006-12-07
EP1893198A2 (fr) 2008-03-05
EA014772B1 (ru) 2011-02-28
TNSN07447A1 (en) 2009-03-17
WO2006130532A3 (fr) 2007-11-22
KR20100018057A (ko) 2010-02-16
US20130109730A1 (en) 2013-05-02
MX2007015085A (es) 2008-01-17
JP5869469B2 (ja) 2016-02-24
BRPI0610873A2 (pt) 2010-08-03
JP2008542380A (ja) 2008-11-27
KR20080003933A (ko) 2008-01-08
NO20076595L (no) 2007-12-20
US20080199428A1 (en) 2008-08-21

Similar Documents

Publication Publication Date Title
MA29542B1 (fr) Traitement des maladies hepatiques dans la pathogenese desquelles le fer joue un role
MA30504B1 (fr) Compositions pharmaceutiques stabilisees comprenant de la fesoterodine
EP1730163A4 (fr) Sels pharmaceutiques de l'acide 3- o-(3',3'-dimethylsuccinyl)betulinique
MA28437B1 (fr) Composes et leurs procedes d'utilisation
MA32070B1 (fr) Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés
EA200702198A1 (ru) Фармацевтические составы
ECSP066959A (es) Compuestos macrociclicos como inhibidores de la replicación viral
CY1111755T1 (el) Μεθοδοι και συνθεσεις για μειωση ποσοτητων ιικου γονιδιωματος hcv σε ενα κυτταρο στοχο
TNSN08194A1 (fr) Compositions pharmaceutiques solides contenant de la pregabaline
EP1932514A4 (fr) Préparation pharmaceutique destinée à une application cutanée externe comprenant un sucre phosphorylé
BR0317572A (pt) Benzoxazinas e seus derivados como inibidores de pi3ks
DK2024367T3 (da) Tetrahydropyrrolopyrimidindioner og deres anvendelse som inhibitorer af human neutrofil elastase
MA29600B1 (fr) Utilisation de sanglifehrine dans le virus de l'hepatite c
CU20090112A6 (es) Compuestos macrocíclicos como inhibidores de la replicación viral
EP2005962A4 (fr) Agent therapeutique pour affection abdominale inflammatoire
NO20076405L (no) Anvendelse av 24-nor-UDCA
DK1893187T3 (da) Forbedrede antimikrobielle peroxidasepræparater
MA31130B1 (fr) Combinaison comprenant un chelatant du fer et un agent antineoplasique et ses applications
EP1930002A4 (fr) Utilisation d'ester d'acide hydroxybenzoïque et d'analogues pour la fabrication d'un médicament pour la prévention et le traitement d'infection virale
MA33563B1 (fr) 5-(3,4-dichloro-phényl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-éthoxy)-nicotinamide et ses sels utilisés comme agents augmentant le cholestérol hdl
WO2007011884A3 (fr) Compositions de pates pour articles cuits au four a duree de conservation prolongee
NO20080890L (no) Sammensetninger for a redusere forekomsten av medikamentindusert arytmi
FR3050112B1 (fr) Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques
EP1968606A4 (fr) Préparation de sels pharmaceutiques de l'acide 3-o-(3',3'-diméthylsuccinyl)bétulinique
RU2007138263A (ru) Противовоспалительные соединения